Sawai Group Holdings Co., Ltd.
Sawai Group Holdings Co., Ltd.
Your view on SWGHF
Overview
What the company does, where it operates, and who runs it.
About Sawai Group Holdings Co., Ltd.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mitsuo Sawai
- Headquarters
- 5-2-30, Miyahara, Osaka, JP
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Mitsuo Sawai
- Headquarters
- 5-2-30, Miyahara, Osaka, JP
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States.
The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, granules, capsules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, chemotherapeutic agents, etc., as well as vitamin preparations.
It sells its generic drugs to distributors, wholesalers, and retailers in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sawai Group Holdings Co., Ltd., and the rating behind it. SWGHF last traded at $11.52, 21.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sawai Group Holdings Co., Ltd.. Starting points for Sawai Group Holdings Co., Ltd.: P/E 21.0, EPS $73.95, beta 0.04 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sawai Group Holdings Co., Ltd.. Sawai Group Holdings Co., Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sawai Group Holdings Co., Ltd.. Trailing twelve-month EPS for Sawai Group Holdings Co., Ltd. stands at $73.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sawai Group Holdings Co., Ltd.. Sawai Group Holdings Co., Ltd. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sawai Group Holdings Co., Ltd. valued side by side against its closest peers. Sawai Group Holdings Co., Ltd. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sawai Group Holdings Co., Ltd., and how their positions are changing. At a $1.33B market value, institutional positions materially move Sawai Group Holdings Co., Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sawai Group Holdings Co., Ltd. executives and directors. Shares of Sawai Group Holdings Co., Ltd. have traded between $11.52 and $13.40 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sawai Group Holdings Co., Ltd.. Sawai Group Holdings Co., Ltd. is a $1.33B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sawai Group Holdings Co., Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sawai Group Holdings Co., Ltd.. Coverage tracks Sawai Group Holdings Co., Ltd. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.